Robin K Kelley

Affiliations

Division of Hematology/Oncology, University of California San Francisco, San Francisco, California, USA.

Réseau de co-auteurs

Do-Youn Oh 2 collaborations

Ghassan K Abou-Alfa 2 collaborations

Anthony B El-Khoueiry 2 collaborations

Sarina A Piha-Paul 1 collaboration

Makoto Ueno 1 collaboration

David Malka 1 collaboration

Hyun Cheol Chung 1 collaboration

Adnan Nagrial 1 collaboration

Willeke Ros 1 collaboration

Antoine Italiano 1 collaboration

Kazuhiko Nakagawa 1 collaboration

Hope S Rugo 1 collaboration

Filippo de Braud 1 collaboration

Andrea Iolanda Varga 1 collaboration

Aaron Hansen 1 collaboration

Hui Wang 1 collaboration

Suba Krishnan 1 collaboration

Kevin G Norwood 1 collaboration

Toshihiko Doi 1 collaboration

Teresa Macarulla 1 collaboration

Milind M Javle 1 collaboration

Sam J Lubner 1 collaboration

Jorge Adeva 1 collaboration

James M Cleary 1 collaboration

Daniel V Catenacci 1 collaboration

Mitesh J Borad 1 collaboration

John Bridgewater 1 collaboration

William P Harris 1 collaboration

Adrian G Murphy 1 collaboration

Jonathan Whisenant 1 collaboration

Maeve A Lowery 1 collaboration

Lipika Goyal 1 collaboration

Rachna T Shroff 1 collaboration

Bin Fan 1 collaboration

Bin Wu 1 collaboration

Christina X Chamberlain 1 collaboration

Liewen Jiang 1 collaboration

Camelia Gliser 1 collaboration

Shuchi S Pandya 1 collaboration

Juan W Valle 1 collaboration

Andrew X Zhu 1 collaboration

Robin Kate Kelley 1 collaboration

Baek-Yeol Ryoo 1 collaboration

Philippe Merle 1 collaboration

Joong-Won Park 1 collaboration

Luigi Bolondi 1 collaboration

Stephen L Chan 1 collaboration

Ho Yeong Lim 1 collaboration

Ari D Baron 1 collaboration

Francis Parnis 1 collaboration

Jennifer Knox 1 collaboration

Stéphane Cattan 1 collaboration

Thomas Yau 1 collaboration

Julie C Lougheed 1 collaboration

Steven Milwee 1 collaboration

Ann-Lii Cheng 1 collaboration

Tim Meyer 1 collaboration

Robin K Kelley

Affiliations

Publications (3)

Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies.

Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.

Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial.

Réseau de co-auteurs